Found: 22
Select item for more details and to access through your institution.
NAD<sup>+</sup>-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.
- Published in:
- Cells (2073-4409), 2015, v. 4, n. 3, p. 520, doi. 10.3390/cells4030520
- By:
- Publication type:
- Article
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
- Published in:
- Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
- By:
- Publication type:
- Article
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy.
- Published in:
- Oncology & Therapy, 2024, v. 12, n. 3, p. 509, doi. 10.1007/s40487-024-00287-2
- By:
- Publication type:
- Article
Response to: Interference of daratumumab on the serum protein electrophoresis.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2017, v. 55, n. 2, p. e29, doi. 10.1515/cclm-2016-1026
- By:
- Publication type:
- Article
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2016, v. 54, n. 6, p. 1095, doi. 10.1515/cclm-2015-1031
- By:
- Publication type:
- Article
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e85, doi. 10.1016/j.clml.2017.03.153
- By:
- Publication type:
- Article
Case Report: Deep Sustained Response to Daratumumab Associated with T-cell Expansion in a Patient with Heavily Treated Relapsed and Refractory Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e86, doi. 10.1016/j.clml.2017.03.155
- By:
- Publication type:
- Article
The Effect of Clinically Relevant Concentrations of Daratumumab on the Performance of Freelite® Immunoassays.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e127, doi. 10.1016/j.clml.2017.03.231
- By:
- Publication type:
- Article
Metabolic Biotinylation Provides a Unique Platform for the Purification and Targeting of Multiple AAV Vector Serotypes.
- Published in:
- Molecular Therapy, 2006, v. 14, n. 1, p. 97, doi. 10.1016/j.ymthe.2006.02.014
- By:
- Publication type:
- Article
High-throughput and efficient multilocus genome-wide association study on longitudinal outcomes.
- Published in:
- Bioinformatics, 2020, v. 36, n. 10, p. 3004, doi. 10.1093/bioinformatics/btaa120
- By:
- Publication type:
- Article
Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression.
- Published in:
- PLoS ONE, 2009, v. 4, n. 4, p. 1, doi. 10.1371/journal.pone.0004992
- By:
- Publication type:
- Article
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 3, p. 475, doi. 10.1111/bjh.15122
- By:
- Publication type:
- Article
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.
- Published in:
- Breast Cancer: Targets & Therapy, 2016, v. 8, p. 12, doi. 10.2147/BCTT.S92414
- By:
- Publication type:
- Article
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
- Published in:
- Experimental Hematology & Oncology, 2018, v. 7, p. 1, doi. 10.1186/s40164-018-0096-7
- By:
- Publication type:
- Article
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.
- Published in:
- British Journal of Clinical Pharmacology, 2015, v. 80, n. 4, p. 687, doi. 10.1111/bcp.12652
- By:
- Publication type:
- Article
Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 5, p. 1108, doi. 10.1002/cpt.2729
- By:
- Publication type:
- Article
Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer.
- Published in:
- FASEB Journal, 2007, v. 21, n. 13, p. 3763, doi. 10.1096/fj.07-8832com
- By:
- Publication type:
- Article
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
- Published in:
- Immunological Reviews, 2016, v. 270, n. 1, p. 95, doi. 10.1111/imr.12389
- By:
- Publication type:
- Article
Efficient algorithms for covariate analysis with dynamic data using nonlinear mixed-effects model.
- Published in:
- Statistical Methods in Medical Research, 2021, v. 30, n. 1, p. 233, doi. 10.1177/0962280220949898
- By:
- Publication type:
- Article
CNV Radar: an improved method for somatic copy number alteration characterization in oncology.
- Published in:
- BMC Bioinformatics, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s12859-020-3397-x
- By:
- Publication type:
- Article